Viking Therapeutics (VKTX) may have exploded from a low of about $10 to $72 so far. But it’s still cheap with substantial potential.
We already know interest in weight loss medications is through the roof. In fact, according to Goldman Sachs, at current pace the market could be worth about $100 billion by 2030.
With Viking Therapeutics, the company is seeing good success with its GLP-1 obesity drug trials. It already reported that its Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints. It also said patients receiving VK-2735 demonstrated weight loss after 13 weeks, rating up to 14.7% from baseline weight.
VKTX is about to start Phase 2 trials of its once-a-day weight loss pill. Viking said patients who received the pill once a day lost up to 5.3% of their weight on average, or up to 3.3% more than those who took a placebo, at 28 days, as noted by CNBC.